Seeking Alpha

Apricus Biosciences jumps on German phase approval for Vitaros

  • Apricus Biosciences (APRI) gets national phase approval (the company's fifth) in Germany for Vitaros.
  • The company says the five remaining European phase approvals should be obtainable in Q4 and Q1 2014.
  • Vitaros' application for marketing approval is approved under the Decentralized Procedure. The Netherlands is the RMS.
  • APRI has multiple partners for the ED treatment including Takeda (TKPHF.PK), Sandoz, and Abbott (ABT). (PR)
  • APRI +10% premarket.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|